Research programme: autoimmune disorder therapeutic proteins - Momenta Pharmaceuticals

Drug Profile

Research programme: autoimmune disorder therapeutic proteins - Momenta Pharmaceuticals

Alternative Names: M230; Selective Immunomodulator of Fc receptors - Momenta Pharmaceuticals; SIF3 - Momenta Pharmaceuticals

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Fc receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Preclinical Autoimmune disorders; Epidermolysis bullosa; Rheumatoid arthritis

Most Recent Events

  • 05 Jan 2017 CSL enters into agreement to in-license M 230
  • 17 Nov 2016 Preclinical trials in Epidermolysis bullosa in USA (Parenteral)
  • 17 Nov 2016 Preclinical trials in Rheumatoid arthritis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top